Glimepiride 4 MG / pioglitazone 30 MG Oral Tablet — RxCUI 647239
RxNorm drug concept · Semantic clinical drug
RxCUI 647239
Semantic clinical drug · SCD
● Current RxNorm concept 4 FDA products
6 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI647239
Official nameGlimepiride 4 MG / pioglitazone 30 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asglimepiride 4 MG / pioglitazone (as pioglitazone hydrochloride) 30 MG Oral Tablet; pioglitazone HCl 30 MG / glimepiride 4 MG Oral Tablet
FDA products mapped4
Package NDCs mapped6
Reported Medicaid activity (SDUD)809 prescriptions · 4 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Glimepiride: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Glimepiride helps your pancreas release more insulin after meals, which brings your blood sugar down. It's specifically for type 2 diabetes and is always meant to work alongside —...
- What exactly is glimepiride supposed to do for me?
- Yes, timing really matters with this one. You should take glimepiride with your breakfast or your first main meal of the day — every day. Taking it without eating raises your risk...
- When should I take it, and does it matter if I take it with food?
🕸️ Concept Web — How Glimepiride 4 MG / pioglitazone 30 MG Oral Table... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Glimepiride 4 MG / pioglitazone 30 MG Oral Tablet
RxCUI 647239 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 3
The active substance itself — no strength, form, or brand attached yet.
-
Glimepiride
25789IN -
Pioglitazone
33738IN -
Glimepiride / pioglitazone
647235MIN
-
Glimepiride
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Duetact
647208BN
-
Duetact
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Glimepiride / pioglitazone Oral Tablet
647236SCDF -
Glimepiride / pioglitazone Oral Product
1157240SCDG -
Glimepiride / pioglitazone Pill
1157241SCDG -
Glimepiride / pioglitazone Oral Tablet [Duetact]
731462SBDF -
Duetact Oral Product
1166403SBDG -
Duetact Pill
1166404SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Glimepiride / pioglitazone Oral Tablet
-
Clinical & branded drugs 4
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Glimepiride 4 MG
315979SCDC -
Pioglitazone 30 MG
331478SCDC -
Glimepiride 4 MG / pioglitazone 30 MG Oral Tablet [Duetact]
731457SBD -
Glimepiride 4 MG / pioglitazone 30 MG [Duetact]
731455SBDC
-
Glimepiride 4 MG
Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Glimepiride 4 MG
SCDC · 315979 -
Pioglitazone 30 MG
SCDC · 331478 -
Glimepiride / pioglitazone Oral Tablet
SCDF · 647236 -
Glimepiride / pioglitazone Oral Product
SCDG · 1157240 -
Glimepiride / pioglitazone Pill
SCDG · 1157241
Brand-Name Concepts
-
Glimepiride 4 MG / pioglitazone 30 MG Oral Tablet [Duetact]
SBD · 731457 -
Glimepiride 4 MG / pioglitazone 30 MG [Duetact]
SBDC · 731455 -
Glimepiride / pioglitazone Oral Tablet [Duetact]
SBDF · 731462 -
Duetact Oral Product
SBDG · 1166403 -
Duetact Pill
SBDG · 1166404 -
Duetact
BN · 647208
📦 FDA Products & Package NDCs
4 products · 6 package NDCs
6 package NDCs map to RxCUI 647239 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 64764-0302-30 | 30 TABLET in 1 BOTTLE (64764-302-30) | Duetact | Takeda Pharmaceuticals America, Inc. | 2006-07-28 |
| 64764-0302-90 | 90 TABLET in 1 BOTTLE (64764-302-90) | Duetact | Takeda Pharmaceuticals America, Inc. | 2006-07-28 |
| 64764-0304-30 | 30 TABLET in 1 BOTTLE (64764-304-30) | Duetact | Takeda Pharmaceuticals America, Inc. | 2006-07-28 |
| 64764-0304-90 | 90 TABLET in 1 BOTTLE (64764-304-90) | Duetact | Takeda Pharmaceuticals America, Inc. | 2006-07-28 |
| 66993-0821-30 | 30 TABLET in 1 BOTTLE (66993-821-30) | pioglitazone and glimepiride | Prasco Laboratories | 2015-08-04 |
| 66993-0822-30 | 30 TABLET in 1 BOTTLE (66993-822-30) | pioglitazone and glimepiride | Prasco Laboratories | 2015-08-04 |
Observed labelers:
Takeda Pharmaceuticals America, Inc. (4) ·
Prasco Laboratories (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.